Pharmaceuticals

Meningococcal Vaccines Market Forecast 2025–2034: Where Businesses Should Invest Next

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Meningococcal Vaccines Market From 2025 To 2034?

The meningococcal vaccines market has experienced significant growth in recent years. Projections indicate it will expand from $3.89 billion in 2024 to $4.26 billion in 2025, driven by a compound annual growth rate (CAGR) of 9.3%. This historical expansion can be attributed to factors such as disease incidence, global travel trends, enhancements in healthcare infrastructure, epidemic preparedness, and the scope of health insurance coverage.

The market for meningococcal vaccines is projected to experience robust expansion in the coming years. This market is anticipated to reach $6.05 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.2%. Several factors contribute to this projected growth, including the appearance of novel strains, rising globalization, increased healthcare spending, various health programs, and an evolving regulatory environment. Key developments expected during this period encompass personalized vaccines, electronic vaccination records, gene editing advancements, multi-valent vaccine formulations, and subscription-based vaccine access models.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Are The Key Drivers Of Growth In The Meningococcal Vaccines Market?

An expected rise in healthcare spending is poised to accelerate the expansion of the meningococcal vaccine market. Healthcare, in this context, refers to residential care institutions, nursing facilities, and intermediate care facilities for individuals with mental illnesses or retardation. The high cost associated with new vaccine generations, when contrasted with their predecessors, has become central to debates regarding whether their benefits warrant the price. Consequently, assessing the comprehensive social and economic benefits of vaccination is an increasingly vital area of study. Illustratively, healthcare spending in the United States surged by 9.7% to $4.1 trillion, or $12,530 per person, in May 2022, according to an article published by the American Medical Association. This growth pace was notably higher than the 4.3% recorded in 2019. Therefore, this upward trend in healthcare spending is a primary impetus for the growth of the meningococcal vaccine market.

What Are The Leading Segments Analyzed In The Meningococcal Vaccines Market?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Which Trends Are Impacting The Meningococcal Vaccines Market?

Leading companies within the meningococcal vaccines market are focusing on the development of novel vaccines to prevent various serogroups, aiming to enhance their market profitability. These vaccines serve as a prophylactic measure, safeguarding individuals from infections attributed to particular serogroups of the Neisseria meningitidis bacteria. An example of this is Pfizer Inc., a pharmaceutical company based in the US, which secured FDA approval for its PENBRAYA vaccine in October 2023. PENBRAYA stands out as the most extensive U.S.-approved meningococcal vaccine, offering protection across a broad spectrum of serogroups, specifically A, B, C, W, and Y. The FDA’s endorsement was based on strong Phase 2 and 3 trial results, which demonstrated immunogenicity comparable to Trumenba + Menveo for all serogroups, alongside a positive safety profile. Furthermore, Pfizer had announced in September 2022 the encouraging findings from a Phase 3 trial, which assessed PENBRAYA’s safety, tolerability, and immunogenicity against other currently licensed meningococcal vaccines.

Who Are The Key Multinational Companies Dominating The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

What Are The Regional Market Dynamics Impacting The Meningococcal Vaccines Industry?

North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Meningococcal Vaccines Market Report:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2025, By The Business Research Company

Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Pediatric Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report

Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795